Balanced news tone
News Sentiment
130A sentiment intelligence
VERITAS IN SILICO INC news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
Weighted score
45
Balanced news tone
3 relevant articles
News tone and price action are not far from neutral.
78/100 classification confidence.
directly relevant articles
high-authority source matches
+1.4% over one week, +1.2% over four weeks, trend inactive, and below fair value.
Takeda Ends Veritas In Silico Pact As mRNA Focus And Valuation Watched
Market Reaction
Balanced read
News tone and price action are not far from neutral.
Primary event
Market update
78/100 classification
One-week reaction
1.4%
Price digesting
Trend fit
Trend inactive
1.2% over four weeks
Fair value
-48.5%
Below fair value
Value support
Sentiment Mix
Positive, neutral, negative
Positive
0
Neutral
2
Negative
1
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
Above 50
Neutral zone
Below 50
News Tape
Relevant headlines
Market source
Direct company coverage
Takeda Ends Veritas In Silico Pact As mRNA Focus And Valuation Watched
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 21 Apr 2026 07:00
- Source
- Market source
BioSpace
Direct company coverage
Takeda continues to prune partnerships, cuts ties with mRNA-targeting Veritas In Silico
- Tone
- Negative 34/100
- Event
- Market update
- Published
- 15 Apr 2026 07:00
- Source
- BioSpace
TipRanks
Direct company coverage
Veritas In Silico Launches First In-House Nucleic Acid Drug Project
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 16 Jun 2025 07:00
- Source
- TipRanks